Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab 150 mg as Compared With Inclisiran: Comparative Evaluation Via Target-Trial Emulation and G-Computation

The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.

Inclusion Criteria:

• Participants initiating alirocumab 150 mg or inclisiran.
• Participants with at least once LDL-C measurement during 365 days before index.
• Participants who continuously enrolled in medical and pharmacy benefits for at least 365 days pre index.

Exclusion Criteria:

• Participants with unknown sex, geographic region, or insurance type, and age < 18 years at index.
• Participants with exposure to evolocumab before index.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.